TDARX, Inc., In the Matter of
TDARX, Inc., settled Federal Trade Commission allegations that the company made false claims in connection with the EU-U.S. Privacy Shield framework.
TDARX, Inc., settled Federal Trade Commission allegations that the company made false claims in connection with the EU-U.S. Privacy Shield framework.
The Federal Trade Commission authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California, alleging in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. On Jan. 2, 2020, the parties abandoned the transaction.